经济观察网溢多利（300381）近7个交易日(截至2026年2月13日)股价呈现震荡走势，最新收盘价为6.77 元，单日下跌0.59%，成交额约3149万元，换手率0.94%。资金流向方面，2月13日主力资金净流出约 159万元，散户资金净流出约184万元，整体资金面偏谨慎。近5日累计跌幅为1.17%，区间振幅收窄， 当前股价处于20日均线(6.93元)下方，技术面短期压力位关注7.19元，支撑位参考6.67元。 机构最新调研显示，溢多利市场关注度一般，舆情中性，机构评级以中性为主(占比100%)。公司近期机 构调研次数行业排名靠前(38/504)，但盈利预测暂无显著调整。2025年业绩预告显示全年净亏损区间为 1300万-2600万元，主要受下游需求不足及非经常性损益拖累，但主营业务毛利率保持46.51%，财务结 构稳健(负债率8.95%)。中长期需关注其在生物酶制剂、半导体材料等新兴领域的业务拓展进展。 机构观点 以上内容基于公开资料整理，不构成投资建议。 ...

Core Viewpoint - The article highlights the achievements and future prospects of Shandong Aobo Biotechnology Co., Ltd., a subsidiary of Aokete Group, emphasizing its commitment to technological innovation and global market expansion in the field of biological enzyme preparations and functional food materials [2][3] Group 1: Company Overview - Shandong Aobo Biotechnology was established in 2014 and focuses on biological enzyme preparations, functional foods, and biopharmaceutical raw materials, exporting products to over 80 countries and regions [2] - The company has built a comprehensive quality control system from strain cultivation to product testing, achieving multiple international certifications such as ISO9001 and KOSHER [2] Group 2: Technological Innovation - Aobo Biotechnology's functional sweetener project utilizes advanced domestic technologies like membrane filtration and ion exchange, achieving a product purity of over 99%, filling a gap in the domestic industry [2] - The project is recognized as a preferred project for the transformation of new and old kinetic energy in Shandong Province, with an expected annual sales revenue of 250 million yuan [2] Group 3: Market Position and Recognition - The company has been awarded the title of National High-tech Enterprise and Shandong Province Gazelle Enterprise, and was recently included in the pilot enterprise list for the construction of a green, low-carbon, high-quality development zone in Shandong Province [3] - Aobo Biotechnology showcased its functional food raw materials at the 22nd World Pharmaceutical Raw Materials China Exhibition, securing intention orders exceeding 100 million yuan due to its "zero additives, high activity" characteristics [3] Group 4: Future Outlook - The company aims to continue leveraging "new quality productivity" to activate new development momentum, promoting more "Made in China" biological products globally and contributing to the global health industry [3]